Cargando…

CRISPR-Cas systems: ushering in the new genome editing era

In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez Rojo, Fernando, Nyman, Rikard Karl Martin, Johnson, Alexander Arthur Theodore, Navarro, Maria Pazos, Ryan, Megan Helen, Erskine, William, Kaur, Parwinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067892/
https://www.ncbi.nlm.nih.gov/pubmed/29968520
http://dx.doi.org/10.1080/21655979.2018.1470720
_version_ 1783343186131812352
author Perez Rojo, Fernando
Nyman, Rikard Karl Martin
Johnson, Alexander Arthur Theodore
Navarro, Maria Pazos
Ryan, Megan Helen
Erskine, William
Kaur, Parwinder
author_facet Perez Rojo, Fernando
Nyman, Rikard Karl Martin
Johnson, Alexander Arthur Theodore
Navarro, Maria Pazos
Ryan, Megan Helen
Erskine, William
Kaur, Parwinder
author_sort Perez Rojo, Fernando
collection PubMed
description In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided.
format Online
Article
Text
id pubmed-6067892
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-60678922019-07-03 CRISPR-Cas systems: ushering in the new genome editing era Perez Rojo, Fernando Nyman, Rikard Karl Martin Johnson, Alexander Arthur Theodore Navarro, Maria Pazos Ryan, Megan Helen Erskine, William Kaur, Parwinder Bioengineered Commentary In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided. Taylor & Francis 2018-07-03 /pmc/articles/PMC6067892/ /pubmed/29968520 http://dx.doi.org/10.1080/21655979.2018.1470720 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Perez Rojo, Fernando
Nyman, Rikard Karl Martin
Johnson, Alexander Arthur Theodore
Navarro, Maria Pazos
Ryan, Megan Helen
Erskine, William
Kaur, Parwinder
CRISPR-Cas systems: ushering in the new genome editing era
title CRISPR-Cas systems: ushering in the new genome editing era
title_full CRISPR-Cas systems: ushering in the new genome editing era
title_fullStr CRISPR-Cas systems: ushering in the new genome editing era
title_full_unstemmed CRISPR-Cas systems: ushering in the new genome editing era
title_short CRISPR-Cas systems: ushering in the new genome editing era
title_sort crispr-cas systems: ushering in the new genome editing era
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067892/
https://www.ncbi.nlm.nih.gov/pubmed/29968520
http://dx.doi.org/10.1080/21655979.2018.1470720
work_keys_str_mv AT perezrojofernando crisprcassystemsusheringinthenewgenomeeditingera
AT nymanrikardkarlmartin crisprcassystemsusheringinthenewgenomeeditingera
AT johnsonalexanderarthurtheodore crisprcassystemsusheringinthenewgenomeeditingera
AT navarromariapazos crisprcassystemsusheringinthenewgenomeeditingera
AT ryanmeganhelen crisprcassystemsusheringinthenewgenomeeditingera
AT erskinewilliam crisprcassystemsusheringinthenewgenomeeditingera
AT kaurparwinder crisprcassystemsusheringinthenewgenomeeditingera